Terzepatide is currently the first hybrid peptide with dual GIP/GLP-1 receptor co-agonist approved for improving glycaemic control in patients with T2D, as an adjunct to diet and exercise, in the United States, Europe and the United Arab Emirates [24]. This evidence concerns the gene GIP and type 2 diabetes mellitus.